Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Freenome, Inc.FRNM · Entity 4644 | Director | July 20, 2026 | July 28, 2026 |
| NEOGENOMICS INCNEO · Entity 2096 | Director | August 01, 2021 | August 13, 2021 |
| RENOVARE ENVIRONMENTAL, INC.BHTG · Entity 128802 | Director | May 24, 2018 | May 25, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Freenome, Inc.
Report date July 20, 2026 · Filed July 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 20,867 |
Reported balance
Holding disclosure · report date 2026-07-20 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 20,867 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.00 · Expires 2035-05-28 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-07-20 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F3: This option was previously amended, pursuant to which the exercise price of the option will be automatically reduced to $8.45 upon the occurrence of certain events. F1: The shares subject to this option are fully vested. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.00 · Expires 2035-05-28 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-07-20 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F3: This option was previously amended, pursuant to which the exercise price of the option will be automatically reduced to $8.45 upon the occurrence of certain events. F2: 25% of the shares subject to this option shall vest and become exercisable on June 3, 2025 with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.45 · Expires 2035-10-23 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-07-20 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F1: The shares subject to this option are fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option are fully vested.
F2: 25% of the shares subject to this option shall vest and become exercisable on June 3, 2025 with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
F3: This option was previously amended, pursuant to which the exercise price of the option will be automatically reduced to $8.45 upon the occurrence of certain events.
NEOGENOMICS INC
Report date August 01, 2021 · Filed August 13, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,468,797 |
Reported balance
After 2021-08-01 transaction · row 2
1 source rowRow 2 · 2021-08-01 · Tax withholding · Disposed 5,919 · Balance 2,468,797 F1: Shares surrendered to NeoGenomics Inc. to satisfy the tax obligations in connection with the August 1, 2021 vesting of restricted stock. |
| Common StockSEC Table I · non-derivative | IndirectCustodial Account for Child | 15,000 |
Reported balance
Holding disclosure · report date 2021-08-01 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 15,000 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.03 · Expires 2023-02-26 | Direct | 500,000 |
Reported balance
Holding disclosure · report date 2021-08-01 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 500,000 F2: On February 26, 2018, Mr. VanOort was granted 500,000 stock options. These options vested ratably over the first three anniversary dates of the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.60 · Expires 2024-03-01 | Direct | 231,567 |
Reported balance
Holding disclosure · report date 2021-08-01 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 231,567 F3: On March 1, 2019, Mr. VanOort was granted 231,567 stock options. These options vest ratably over the first four anniversary dates of the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.33 · Expires 2027-03-02 | Direct | 225,084 |
Reported balance
Holding disclosure · report date 2021-08-01 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 225,084 F4: On March 2, 2020, Mr. VanOort was granted 225,084 stock options. These options vest ratably over the first four anniversary dates of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares surrendered to NeoGenomics Inc. to satisfy the tax obligations in connection with the August 1, 2021 vesting of restricted stock.
F2: On February 26, 2018, Mr. VanOort was granted 500,000 stock options. These options vested ratably over the first three anniversary dates of the grant date.
F3: On March 1, 2019, Mr. VanOort was granted 231,567 stock options. These options vest ratably over the first four anniversary dates of the grant date.
F4: On March 2, 2020, Mr. VanOort was granted 225,084 stock options. These options vest ratably over the first four anniversary dates of the grant date.
RENOVARE ENVIRONMENTAL, INC.
Report date May 24, 2018 · Filed May 25, 2018
Jointly reported with CONUNDRUM CAPITAL PARTNERS, LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.0001SEC Table I · non-derivative | IndirectHeld by Conundrum Capital Partners, LLC | 914,427 |
Last balance in matching sequence
After 2018-05-24 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2018-05-24 · Conversion · Acquired 36,364 · Balance 913,228 F2: 36,364 shares at $2.75 per share represent the conversion at maturity of a convertible note initially entered into on August 17, 2017. F1: Douglas M. VanOort holds voting and dispositive control over Conundrum Capital Partners, LLC. Row 2 · 2018-05-24 · Conversion · Acquired 1,199 · Balance 914,427 F3: 1,199 shares at $4.30 per share represent the payment of interest at 8% on the note. F1: Douglas M. VanOort holds voting and dispositive control over Conundrum Capital Partners, LLC. |
| Convertible Promissory NoteSEC Table II · derivative / convertible security · Conversion / exercise price $2.75 · Expires 2018-05-24 | IndirectHeld by Conundrum Capital Partners, LLC | 0 |
Reported balance
After 2018-05-24 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-05-24 · Conversion · Disposed 1 · Balance 0 F1: Douglas M. VanOort holds voting and dispositive control over Conundrum Capital Partners, LLC. |
Filing footnotes · ownership attribution and instrument terms
F1: Douglas M. VanOort holds voting and dispositive control over Conundrum Capital Partners, LLC.
F2: 36,364 shares at $2.75 per share represent the conversion at maturity of a convertible note initially entered into on August 17, 2017.
F3: 1,199 shares at $4.30 per share represent the payment of interest at 8% on the note.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 25, 2017 Filed May 30, 2017 21:08 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantRestricted Stock · Derivative | 197,042 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-036159 · doc4.xml · derivative · entry 5 VAN OORT DOUGLAS M · CIK 0001518733 · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,042 Underlying: Common Stock · 197,042 shares Expires not disclosed F5 · security: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit. F6 · derivative.exercise_date: Restricted stock will vest as follows; 65,680 units will vest on May 25, 2018 and 65,681 units will vest on May 25, 2019 and 2020. F7 · derivative.expiration_date: These restricted stock units will terminate upon the earliest of death, termination of employment or the last vesting date. Read SEC document |
| April 28, 2017 Filed May 2, 2017 20:50 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Option (Right to Buy) · Derivative | 500,000 | $7.52 Strike: $7.52 | $3,760,000.00 |
DisclosureSEC source: 0001209191-17-029237 · doc4.xml · derivative · entry 4 VAN OORT DOUGLAS M · CIK 0001518733 · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2022-04-28 F4 · derivative.exercise_date: On April 28, 2017, Mr. VanOort was granted 500,000 stock options. These options vest ratably over the first three anniversary dates of the grant date. Read SEC document |
| February 02, 2017 Filed Feb 7, 2017 02:25 UTC | NEOGENOMICS INC NEO · Entity 2096 | OtherStock Option (Right to Buy) · Derivative | 200,000 | $1.71 Strike: $1.71 | $342,000.00 |
DisclosureSEC source: 0001209191-17-008193 · doc4.xml · derivative · entry 6 VAN OORT DOUGLAS M · CIK 0001518733 · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 200,000 shares Expires 2017-02-14 Read SEC document |
| February 02, 2017 Filed Feb 7, 2017 02:25 UTC | NEOGENOMICS INC NEO · Entity 2096 | Tax withholdingCommon Stock | 42,015 | $8.14 | $342,002.10 |
DisclosureSEC source: 0001209191-17-008193 · doc4.xml · nonDerivative · entry 4 VAN OORT DOUGLAS M · CIK 0001518733 · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,832,985 F3 · shares: Shares withheld by NeoGenomics Inc. to satisfy the cost of shares in connection with the February 2, 2017 stock option exercise. F4 · price: Closing stock price on February 1, 2017. Read SEC document |
| February 02, 2017 Filed Feb 7, 2017 02:25 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 200,000 | $1.71 | $342,000.00 |
DisclosureSEC source: 0001209191-17-008193 · doc4.xml · nonDerivative · entry 3 VAN OORT DOUGLAS M · CIK 0001518733 · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,875,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.